Skip Navigation

JNCI Journal of the National Cancer Institute 2008 100(13):907; doi:10.1093/jnci/djn226
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Imatinib-Resistant Leukemia and LYN Kinase

The tyrosine kinase inhibitor imatinib is used to treat chronic myelogenous leukemia (CML). Failure of imatinib treatment is associated with mutations in the BCR-ABL kinase in some, but not all, CML patients. The LYN kinase regulates survival and responsiveness of CML cells to inhibition of the BCR-ABL kinase, and differences in LYN regulation have been found between imatinib-sensitive and imatinib-resistant CML cell lines. Wu et al. (p. 926) investigated whether LYN kinase was involved in imatinib-resistant CML by evaluating mononuclear cells from 12 imatinib-resistant CML patients with BCR-ABL mutation–negative leukemia and . . . [Full Text of this Article]

CHD5 is a Tumor Suppressor Gene for Neuroblastoma

Immunization with GCC to Prevent Colon Cancer Metastasis

Fine Mapping of a Cancer Susceptibity Locus

NSAID Use and Melanoma Incidence in a Cohort Study

Evaluating Large Epidemiological Studies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?